{"gene":"BTN2A1","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":2021,"finding":"BTN2A1 is required for BTN3A-mediated Vγ9Vδ2 T cell cytotoxicity against cancer cells; expression of the BTN2A1/BTN3A1 complex is sufficient to trigger Vγ9Vδ2 TCR activation; BTN2A1 interacts with all BTN3A isoforms (BTN3A1, BTN3A2, BTN3A3), and this interaction is enhanced by phosphoantigens; B30.2 domains of both BTN2A1 and BTN3A1 are required for phosphoantigen responsiveness; anti-BTN2A1 monoclonal antibodies inhibit Vγ9Vδ2 TCR activation by blocking BTN2A1 binding to the Vγ9Vδ2 TCR","method":"Co-immunoprecipitation, cell cytotoxicity assays, BTN2A1/BTN3A1 complex reconstitution in cancer cells, anti-BTN2A1 mAb blocking experiments","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, reconstitution, functional blocking with multiple orthogonal methods, moderate-to-strong evidence","pmids":["34260935"],"is_preprint":false},{"year":2007,"finding":"BTN2A1 is a cell surface glycoprotein that acts as a novel ligand for DC-SIGN on immature monocyte-derived dendritic cells; the interaction requires Ca2+ and is mediated by high-mannose oligosaccharides on BTN2A1; tumor cell BTN2A1 carries more high-mannose moieties than normal endothelial cells, governing recognition by DC-SIGN","method":"Ig-fusion protein binding assay, DC-SIGN-transfectant binding, antibody inhibition, glycosylation analysis","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — direct binding assays with transfectants, Ab blocking, and glycosylation characterization using multiple orthogonal methods","pmids":["17785817"],"is_preprint":false},{"year":2023,"finding":"NMR and mutagenesis establish a BTN2A1-IgV/BTN3A1-IgV structural model compatible with cis cell-surface association; TCR and BTN3A1-IgV binding to BTN2A1-IgV are mutually exclusive due to binding site proximity/overlap; BTN2A1-IgV/BTN3A1-IgV interaction is non-essential for recognition; a molecular surface on BTN3A1-IgV is essential for phosphoantigen sensing, supporting a composite-ligand model where intracellular phosphoantigen detection coordinates weak extracellular germline TCR/BTN2A1 and clonotypically influenced TCR/BTN3A-mediated interactions","method":"NMR, molecular modeling, mutagenesis, TCR binding assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1 — NMR structure with mutagenesis and functional validation in a single rigorous study","pmids":["36995939"],"is_preprint":false},{"year":2023,"finding":"BTN2A1 forms a disulfide-linked homodimer via its B30.2 domain; homodimerization of the BTN2A1 intracellular B30.2 domain is required for phosphoantigen detection; L325G mutation in the BTN2A1 B30.2 domain prevents homodimerization and blocks binding to HMBPP-bound BTN3A1; HMBPP (phosphoantigen) binds BTN3A1 but not BTN2A1; cysteine residues C247 and C265 mediate the disulfide-linked homodimer but are not required for T cell IFN-γ stimulation","method":"NMR, size exclusion chromatography, site-directed mutagenesis, isothermal titration calorimetry, [31P]-NMR, ELISA (T cell IFN-γ)","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with NMR and mutagenesis, multiple orthogonal methods in single study","pmids":["37171180"],"is_preprint":false},{"year":2024,"finding":"Anti-BTN2A1 monoclonal antibody engagement induces SYK recruitment and sequential SYK and ERK phosphorylation in M2-like macrophages, reprogramming them toward an M1-like phenotype; inhibition of SYK or ERK abolishes M2 reprogramming upon BTN2A1 engagement; BTN2A1-reprogrammed macrophages enhance T cell proliferation and IFNγ secretion","method":"Anti-BTN2A1 mAb treatment, phosphoprotein analysis (SYK/ERK phosphorylation), kinase inhibitor experiments, in vitro macrophage differentiation assays, ex vivo TAM experiments","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — defined signaling pathway with pharmacological inhibitor validation and multiple functional readouts","pmids":["39325623"],"is_preprint":false},{"year":2022,"finding":"A heterodimeric BTN2A1/BTN3A1 fusion protein provides 'signal 1' to the Vγ9Vδ2 TCR but requires costimulatory signals via CD28 or NKG2D for full T cell activation; a bispecific BTN2A1/BTN3A1-Fc-CD19scFv engager promotes granzyme B-mediated killing of CD19+ lymphoma cells","method":"Tumor cell-free assay with BTN2A1/BTN3A1 heterodimeric fusion protein, CD28/NKG2D costimulation experiments, granzyme B cytotoxicity assay","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 — reconstituted heterodimer functional assay but single lab, limited mechanistic depth","pmids":["36096643"],"is_preprint":false},{"year":2024,"finding":"Anti-BTN2A1 agonist antibody 107G3B5 enhances Vγ9Vδ2 T cell interaction with and killing of tumor cells; Vγ9Vδ2 T cells activated by this antibody trigger caspase 3/7 activation in tumor cells, causing tumor cell death by pyroptosis","method":"Cytotoxicity assays, holotomographic microscopy, caspase 3/7 activation assay","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 — clean KO/antibody experiments with defined mechanistic phenotype (pyroptosis via caspase 3/7), single lab","pmids":["39302336"],"is_preprint":false},{"year":2025,"finding":"BTN2A1 expression on lymphocytes increases via trogocytosis from activated myeloid cells upon CD3/CD28 stimulation; BTN2A1 acquired by BTN2A1-KO B cells through trogocytosis from monocytes confers higher sensitivity to Vγ9Vδ2 T cell lysis; trogocytosis-mediated BTN2A1 acquisition by circulating lymphocytes involves activated monocytes","method":"BTN2A1-knockout B cell line, trogocytosis assay, flow cytometry, cytotoxicity assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 — KO cell line with trogocytosis and functional cytotoxicity readout, single lab","pmids":["41066236"],"is_preprint":false},{"year":2025,"finding":"19F NMR of BTN3A1 point mutants shows that residues W421, T449, and T506 in the BTN3A1 B30.2 domain are conformationally influenced by HMBPP and BTN2A1 association; W421 is at the BTN2A1-binding interface; T506 conformational change upon HMBPP/BTN2A1 binding indicates a larger conformational change in BTN3A1 B30.2 domain propagated beyond the direct phosphoantigen binding site","method":"19F solution NMR, BTN3A1 point mutants, binding affinity measurements","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 1 — in vitro NMR with mutagenesis and binding affinity measurements, mechanistically detailed","pmids":["40079188"],"is_preprint":false},{"year":2024,"finding":"Cryo-EM structure of full-length BTN3A1-BTN3A2-BTN2A1 complex shows that phosphoantigen HMBPP bridges the intracellular B30.2 domains of BTN3A1 and BTN2A1; upon TCR engagement, BTN3A2-BTN2A1 ectodomain interaction dissociates, allowing BTN2A1 to bind the lateral surface of the Vγ9 chain while BTN3A2 binds the apical surface of the Vδ2 chain, constituting a 'pliers-like gripping' mechanism for TCR activation; BTN3A2 identified as a bona fide TCR ligand","method":"Cryo-EM structural determination of full-length BTN3A1-BTN3A2-BTN2A1 complex and BTN multimer-TCR complex","journal":"bioRxiv","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structures at multiple states providing mechanistic model, strong structural evidence","pmids":[],"is_preprint":true},{"year":2024,"finding":"Single oncogenic mutations in healthy organoids are sufficient to upregulate surface BTN2A1 and enable Vγ9Vδ2 TCR binding; full T cell activation additionally requires phosphorylation of juxtamembrane (JTM) amino acids of BTN3A1 leading to activating BTN2A1/BTN3A1 heterodimerization; protein interactome mapping identified PHLDB2, SYNJ2, and CARMIL1 as key regulators of dual surface dynamics of BTN2A1 and BTN3A1 during early transformation","method":"Genetically engineered step-wise mutagenesis organoid models, surface BTN2A1 upregulation assays, TCR binding assays, protein interactome mapping","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — functional organoid models with interactome mapping, preprint not yet peer-reviewed","pmids":[],"is_preprint":true},{"year":2025,"finding":"ICT01 antibody binds a unique region in the extracellular domain of BTN3As, destabilizes the BTN2A1-BTN3As interface, and facilitates Vγ9Vδ2 TCR engagement, thereby activating Vγ9Vδ2 T cells independently of phosphoantigens","method":"Structural analysis, biochemical assays, cellular activation assays","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1-2 — structural and biochemical characterization but preprint only","pmids":[],"is_preprint":true}],"current_model":"BTN2A1 is a transmembrane butyrophilin that forms a heteromeric complex with BTN3A1 (and BTN3A2) at the cell surface; intracellularly, phosphoantigen (HMBPP) bridges the B30.2 domains of BTN3A1 and BTN2A1, inducing conformational changes that prime the extracellular BTN2A1 IgV domain to directly bind the Vγ9 chain of the Vγ9Vδ2 TCR as a germline ligand (while BTN3A2 engages the Vδ2 chain), together triggering γδ T cell cytotoxicity; BTN2A1 homodimerization via its B30.2 domain is required for phosphoantigen responsiveness, BTN2A1 also acts as a ligand for DC-SIGN on dendritic cells via high-mannose glycosylation, and in macrophages BTN2A1 engagement signals through SYK and ERK to modulate macrophage polarization."},"narrative":{"teleology":[{"year":2007,"claim":"Establishing that BTN2A1 is a cell-surface glycoprotein recognized by the innate immune receptor DC-SIGN on dendritic cells, dependent on high-mannose glycosylation, provided the first evidence that BTN2A1 participates in immune cell communication.","evidence":"Ig-fusion binding assays, DC-SIGN transfectant binding, antibody blocking, and glycosylation analysis","pmids":["17785817"],"confidence":"High","gaps":["Functional consequence of BTN2A1–DC-SIGN interaction on dendritic cell maturation or antigen presentation not determined","Whether DC-SIGN engagement modulates BTN2A1 signaling in the BTN2A1-expressing cell unknown"]},{"year":2021,"claim":"Identification of BTN2A1 as an obligate co-receptor with BTN3A1 for Vγ9Vδ2 TCR activation resolved the long-standing question of how phosphoantigen sensing is translated into γδ T cell recognition, showing that BTN2A1 directly contacts the TCR and that its B30.2 domain is required for phosphoantigen responsiveness.","evidence":"Co-immunoprecipitation, BTN2A1/BTN3A1 reconstitution in cancer cells, anti-BTN2A1 mAb blocking, and cytotoxicity assays","pmids":["34260935"],"confidence":"High","gaps":["Structural basis of the BTN2A1–TCR interaction not resolved at this point","Relative contributions of BTN3A isoforms (BTN3A1 vs BTN3A2 vs BTN3A3) to the complex not delineated"]},{"year":2022,"claim":"Demonstrating that a heterodimeric BTN2A1/BTN3A1 fusion protein delivers 'signal 1' to the Vγ9Vδ2 TCR but requires costimulation for full T cell activation clarified that BTN2A1/BTN3A1 functions analogously to peptide–MHC for γδ T cells.","evidence":"Tumor cell-free reconstitution with heterodimeric fusion protein, CD28/NKG2D costimulation, granzyme B cytotoxicity assay","pmids":["36096643"],"confidence":"Medium","gaps":["Costimulatory requirements not validated in vivo","Whether the fusion protein fully recapitulates native complex geometry remains uncertain"]},{"year":2023,"claim":"NMR-based structural mapping revealed that TCR and BTN3A1-IgV bind overlapping sites on BTN2A1-IgV, establishing mutual exclusivity and supporting a composite-ligand model where intracellular phosphoantigen sensing coordinates distinct extracellular TCR contacts.","evidence":"NMR, molecular modeling, mutagenesis, TCR binding assays","pmids":["36995939"],"confidence":"High","gaps":["Full atomic-resolution structure of the ternary TCR–BTN2A1–BTN3A1 extracellular complex not available from this study","Dynamics of the switch between BTN3A1-bound and TCR-bound states of BTN2A1 not resolved"]},{"year":2023,"claim":"Discovering that BTN2A1 forms a disulfide-linked homodimer via its B30.2 domain, and that homodimerization is required for HMBPP-bound BTN3A1 recognition, established a critical intracellular gating mechanism for phosphoantigen sensing.","evidence":"NMR, size exclusion chromatography, site-directed mutagenesis (L325G), isothermal titration calorimetry, 31P-NMR","pmids":["37171180"],"confidence":"High","gaps":["Whether BTN2A1 homodimerization is regulated by post-translational modifications in vivo not addressed","Stoichiometry of the full signaling complex at the membrane not determined"]},{"year":2024,"claim":"Anti-BTN2A1 antibody engagement on M2-like macrophages was shown to recruit SYK and activate SYK–ERK signaling, reprogramming macrophages toward an M1-like state, revealing a previously unrecognized signaling function for BTN2A1 beyond TCR ligand activity.","evidence":"Anti-BTN2A1 mAb treatment, SYK/ERK phosphoprotein analysis, kinase inhibitor experiments, in vitro and ex vivo macrophage assays","pmids":["39325623"],"confidence":"High","gaps":["Endogenous ligand or physiological trigger for BTN2A1-mediated macrophage signaling not identified","Whether SYK directly binds the BTN2A1 cytoplasmic domain or requires an adaptor unknown"]},{"year":2024,"claim":"Cryo-EM structures of the full-length BTN3A1–BTN3A2–BTN2A1 complex revealed that HMBPP bridges BTN3A1 and BTN2A1 B30.2 domains intracellularly, and upon TCR engagement the BTN3A2–BTN2A1 ectodomain interaction dissociates so that BTN2A1 grips the Vγ9 chain laterally while BTN3A2 contacts the Vδ2 chain apically, establishing a 'pliers-like' activation mechanism.","evidence":"Cryo-EM structural determination of full-length complex and BTN multimer–TCR complex (preprint)","pmids":[],"confidence":"High","gaps":["Preprint not yet peer-reviewed","How membrane lipid environment influences the conformational switch remains unknown","Kinetics of ectodomain dissociation upon phosphoantigen loading not measured"]},{"year":2025,"claim":"19F NMR of BTN3A1 point mutants showed that HMBPP and BTN2A1 association induce conformational changes at residues distant from the phosphoantigen-binding pocket (notably T506), demonstrating allosteric signal propagation through the BTN3A1 B30.2 domain.","evidence":"19F solution NMR with BTN3A1 point mutants and binding affinity measurements","pmids":["40079188"],"confidence":"High","gaps":["How allosteric changes in B30.2 are transmitted across the membrane to the ectodomain not structurally resolved at atomic level","Whether similar allostery occurs in BTN3A2 or BTN3A3 B30.2 domains not tested"]},{"year":2025,"claim":"BTN2A1 can be transferred to lymphocytes via trogocytosis from activated monocytes, and trogocytosis-acquired BTN2A1 is functionally competent to sensitize cells to Vγ9Vδ2 T cell killing, revealing a non-transcriptional mechanism for regulating BTN2A1-dependent γδ T cell surveillance.","evidence":"BTN2A1-knockout B cell line, trogocytosis assay, flow cytometry, cytotoxicity assays","pmids":["41066236"],"confidence":"Medium","gaps":["In vivo relevance of trogocytic BTN2A1 acquisition not demonstrated","Whether trogocytosis transfers the full BTN2A1/BTN3A complex or only BTN2A1 not resolved"]},{"year":null,"claim":"The mechanism by which intracellular phosphoantigen-induced conformational changes in the B30.2 domains are propagated across the membrane to remodel ectodomain architecture, and how BTN2A1's SYK-dependent signaling in macrophages is initiated at the molecular level, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No full transmembrane signaling mechanism linking B30.2 allostery to ectodomain rearrangement","Endogenous trigger for BTN2A1-mediated macrophage SYK signaling unknown","Whether BTN2A1 has a direct cytoplasmic signaling motif or requires adaptor proteins not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,2,5,9]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[4]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,7]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,2,4,5,6]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4]}],"complexes":["BTN2A1–BTN3A1–BTN3A2 heteromeric complex","BTN2A1 homodimer"],"partners":["BTN3A1","BTN3A2","BTN3A3","DC-SIGN","SYK","PHLDB2","SYNJ2","CARMIL1"],"other_free_text":[]},"mechanistic_narrative":"BTN2A1 is a transmembrane butyrophilin family member that functions as a germline ligand for the Vγ9Vδ2 T cell receptor and a key mediator of phosphoantigen-dependent γδ T cell activation. BTN2A1 forms a heteromeric complex with BTN3A isoforms at the cell surface; intracellularly, the microbial phosphoantigen HMBPP bridges the B30.2 domains of BTN3A1 and BTN2A1, inducing conformational changes that prime the BTN2A1 IgV ectodomain to directly engage the Vγ9 chain of the TCR, while BTN3A2 contacts the Vδ2 chain, together triggering cytotoxicity [PMID:34260935, PMID:36995939, PMID:37171180]. BTN2A1 homodimerization via its B30.2 domain is required for phosphoantigen responsiveness, and TCR and BTN3A1-IgV binding sites on BTN2A1-IgV are mutually exclusive, supporting a composite-ligand model of activation [PMID:37171180, PMID:36995939]. Beyond γδ T cell biology, BTN2A1 serves as a ligand for DC-SIGN on dendritic cells through high-mannose glycosylation [PMID:17785817], and antibody-mediated BTN2A1 engagement on macrophages activates SYK–ERK signaling to reprogram M2-like macrophages toward an M1-like phenotype that enhances T cell responses [PMID:39325623]."},"prefetch_data":{"uniprot":{"accession":"Q7KYR7","full_name":"Butyrophilin subfamily 2 member A1","aliases":[],"length_aa":527,"mass_kda":59.6,"function":"","subcellular_location":"Membrane","url":"https://www.uniprot.org/uniprotkb/Q7KYR7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BTN2A1","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/BTN2A1","total_profiled":1310},"omim":[{"mim_id":"613595","title":"BUTYROPHILIN, SUBFAMILY 3, MEMBER A3; BTN3A3","url":"https://www.omim.org/entry/613595"},{"mim_id":"613594","title":"BUTYROPHILIN, SUBFAMILY 3, MEMBER A2; BTN3A2","url":"https://www.omim.org/entry/613594"},{"mim_id":"613593","title":"BUTYROPHILIN, SUBFAMILY 3, MEMBER A1; BTN3A1","url":"https://www.omim.org/entry/613593"},{"mim_id":"613590","title":"BUTYROPHILIN, SUBFAMILY 2, MEMBER A1; BTN2A1","url":"https://www.omim.org/entry/613590"},{"mim_id":"601610","title":"BUTYROPHILIN, SUBFAMILY 1, MEMBER A1; BTN1A1","url":"https://www.omim.org/entry/601610"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BTN2A1"},"hgnc":{"alias_symbol":["BT2.1","BTF1","BTN2.1"],"prev_symbol":[]},"alphafold":{"accession":"Q7KYR7","domains":[{"cath_id":"2.60.40.10","chopping":"32-144","consensus_level":"high","plddt":95.4712,"start":32,"end":144},{"cath_id":"2.60.40.10","chopping":"151-240","consensus_level":"high","plddt":89.4316,"start":151,"end":240},{"cath_id":"2.60.120.920","chopping":"333-501","consensus_level":"high","plddt":89.464,"start":333,"end":501},{"cath_id":"1.20.5","chopping":"255-320","consensus_level":"medium","plddt":82.4177,"start":255,"end":320}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7KYR7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q7KYR7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q7KYR7-F1-predicted_aligned_error_v6.png","plddt_mean":84.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BTN2A1","jax_strain_url":"https://www.jax.org/strain/search?query=BTN2A1"},"sequence":{"accession":"Q7KYR7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q7KYR7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q7KYR7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q7KYR7"}},"corpus_meta":[{"pmid":"34260935","id":"PMC_34260935","title":"BTN2A1, an immune checkpoint targeting Vγ9Vδ2 T cell cytotoxicity against malignant cells.","date":"2021","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/34260935","citation_count":75,"is_preprint":false},{"pmid":"17785817","id":"PMC_17785817","title":"The B7 homolog butyrophilin BTN2A1 is a novel ligand for DC-SIGN.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17785817","citation_count":47,"is_preprint":false},{"pmid":"21211798","id":"PMC_21211798","title":"Association of a polymorphism of BTN2A1 with myocardial infarction in East Asian populations.","date":"2010","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21211798","citation_count":44,"is_preprint":false},{"pmid":"36995939","id":"PMC_36995939","title":"Phosphoantigen sensing combines TCR-dependent recognition of the BTN3A IgV domain and germline interaction with BTN2A1.","date":"2023","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36995939","citation_count":39,"is_preprint":false},{"pmid":"36096643","id":"PMC_36096643","title":"Cutting Edge: Bispecific γδ T Cell Engager Containing Heterodimeric BTN2A1 and BTN3A1 Promotes Targeted Activation of Vγ9Vδ2+ T Cells in the Presence of Costimulation by CD28 or NKG2D.","date":"2022","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/36096643","citation_count":21,"is_preprint":false},{"pmid":"21784758","id":"PMC_21784758","title":"Association of a genetic variant of BTN2A1 with metabolic syndrome in East Asian populations.","date":"2011","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21784758","citation_count":16,"is_preprint":false},{"pmid":"22576629","id":"PMC_22576629","title":"Synergistic effects of genetic variants of APOA5 and BTN2A1 on dyslipidemia or metabolic syndrome.","date":"2012","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22576629","citation_count":12,"is_preprint":false},{"pmid":"24452779","id":"PMC_24452779","title":"Association of a polymorphism of BTN2A1 with dyslipidemia in community-dwelling individuals.","date":"2014","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/24452779","citation_count":12,"is_preprint":false},{"pmid":"21525964","id":"PMC_21525964","title":"Association of a polymorphism of BTN2A1 with hypertension in Japanese individuals.","date":"2011","source":"American journal of hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/21525964","citation_count":10,"is_preprint":false},{"pmid":"22977569","id":"PMC_22977569","title":"Association of a polymorphism of BTN2A1 with dyslipidemia in East Asian populations.","date":"2011","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22977569","citation_count":10,"is_preprint":false},{"pmid":"39325623","id":"PMC_39325623","title":"BTN2A1 targeting reprograms M2-like macrophages and TAMs via SYK and MAPK signaling.","date":"2024","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/39325623","citation_count":9,"is_preprint":false},{"pmid":"37171180","id":"PMC_37171180","title":"Mutations to the BTN2A1 Linker Region Impact Its Homodimerization and Its Cytoplasmic Interaction with Phospho-Antigen-Bound BTN3A1.","date":"2023","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/37171180","citation_count":9,"is_preprint":false},{"pmid":"39302336","id":"PMC_39302336","title":"Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis.","date":"2024","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/39302336","citation_count":9,"is_preprint":false},{"pmid":"21468600","id":"PMC_21468600","title":"Association of polymorphisms of BTN2A1 and ILF3 with myocardial infarction in Japanese individuals with different lipid profiles.","date":"2011","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/21468600","citation_count":9,"is_preprint":false},{"pmid":"24649044","id":"PMC_24649044","title":"Association of a polymorphism of BTN2A1 with chronic kidney disease in community-dwelling individuals.","date":"2013","source":"Biomedical reports","url":"https://pubmed.ncbi.nlm.nih.gov/24649044","citation_count":8,"is_preprint":false},{"pmid":"21557786","id":"PMC_21557786","title":"Association of a genetic variant of BTN2A1 with chronic kidney disease in Japanese individuals.","date":"2011","source":"Nephrology (Carlton, Vic.)","url":"https://pubmed.ncbi.nlm.nih.gov/21557786","citation_count":7,"is_preprint":false},{"pmid":"36760378","id":"PMC_36760378","title":"BTN2A1-BRAF fusion may be a novel mechanism of resistance to osimertinib in lung adenocarcinoma: a case report.","date":"2023","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36760378","citation_count":7,"is_preprint":false},{"pmid":"21672009","id":"PMC_21672009","title":"Association of a polymorphism of BTN2A1 with type 2 diabetes mellitus in Japanese individuals.","date":"2011","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/21672009","citation_count":5,"is_preprint":false},{"pmid":"41226733","id":"PMC_41226733","title":"BTN2A1 and BTN3A1 as Novel Coeliac Disease Risk Loci: An In Silico Analysis.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41226733","citation_count":2,"is_preprint":false},{"pmid":"37634314","id":"PMC_37634314","title":"Frameshift mutations of immunomodulatory BTN2A1, BTN2A2, and BTNL3 genes in colon cancers.","date":"2023","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/37634314","citation_count":1,"is_preprint":false},{"pmid":"39475356","id":"PMC_39475356","title":"BTN2A1: A Novel Target to Boost Tumor Killing Capacity of Human γδ T Cells.","date":"2024","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/39475356","citation_count":1,"is_preprint":false},{"pmid":"41066236","id":"PMC_41066236","title":"BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41066236","citation_count":0,"is_preprint":false},{"pmid":"40079188","id":"PMC_40079188","title":"Investigation of structural and dynamic properties of the Butyrophilin BTN3A1/BTN2A1 cytoplasmic complex by 19F solution NMR.","date":"2025","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/40079188","citation_count":0,"is_preprint":false},{"pmid":"41694338","id":"PMC_41694338","title":"The gamma delta T/NK cell product GADEKILL as a novel immunotherapeutic tool for neuroblastoma patients: role of B7H6 and BTN2A1 in tumor cell killing.","date":"2026","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41694338","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.10.21.681109","title":"Molecular Mechanisms Underlying Human Vγ9Vδ2 T Cell Activation by Butyrophilin-3 (BTN3) Targeted Antibodies","date":"2025-10-21","source":"bioRxiv","url":"https://doi.org/10.1101/2025.10.21.681109","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.10.02.616253","title":"Cryo-EM structural insights into Vγ9Vδ2 TCR activation via multiple butyrophilins","date":"2024-10-03","source":"bioRxiv","url":"https://doi.org/10.1101/2024.10.02.616253","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.06.24309341","title":"Identification of Causal Risk Factors for Pan-Cancers: a Mendelian Randomization Study","date":"2024-07-07","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.06.24309341","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.19.624272","title":"Sensitivity to Vγ9Vδ2TCR T cells is imprinted after single mutations during early oncogenesis","date":"2024-11-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.19.624272","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":16857,"output_tokens":3485,"usd":0.051423},"stage2":{"model":"claude-opus-4-6","input_tokens":6858,"output_tokens":3030,"usd":0.16506},"total_usd":0.216483,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2021,\n      \"finding\": \"BTN2A1 is required for BTN3A-mediated Vγ9Vδ2 T cell cytotoxicity against cancer cells; expression of the BTN2A1/BTN3A1 complex is sufficient to trigger Vγ9Vδ2 TCR activation; BTN2A1 interacts with all BTN3A isoforms (BTN3A1, BTN3A2, BTN3A3), and this interaction is enhanced by phosphoantigens; B30.2 domains of both BTN2A1 and BTN3A1 are required for phosphoantigen responsiveness; anti-BTN2A1 monoclonal antibodies inhibit Vγ9Vδ2 TCR activation by blocking BTN2A1 binding to the Vγ9Vδ2 TCR\",\n      \"method\": \"Co-immunoprecipitation, cell cytotoxicity assays, BTN2A1/BTN3A1 complex reconstitution in cancer cells, anti-BTN2A1 mAb blocking experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, reconstitution, functional blocking with multiple orthogonal methods, moderate-to-strong evidence\",\n      \"pmids\": [\"34260935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BTN2A1 is a cell surface glycoprotein that acts as a novel ligand for DC-SIGN on immature monocyte-derived dendritic cells; the interaction requires Ca2+ and is mediated by high-mannose oligosaccharides on BTN2A1; tumor cell BTN2A1 carries more high-mannose moieties than normal endothelial cells, governing recognition by DC-SIGN\",\n      \"method\": \"Ig-fusion protein binding assay, DC-SIGN-transfectant binding, antibody inhibition, glycosylation analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assays with transfectants, Ab blocking, and glycosylation characterization using multiple orthogonal methods\",\n      \"pmids\": [\"17785817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"NMR and mutagenesis establish a BTN2A1-IgV/BTN3A1-IgV structural model compatible with cis cell-surface association; TCR and BTN3A1-IgV binding to BTN2A1-IgV are mutually exclusive due to binding site proximity/overlap; BTN2A1-IgV/BTN3A1-IgV interaction is non-essential for recognition; a molecular surface on BTN3A1-IgV is essential for phosphoantigen sensing, supporting a composite-ligand model where intracellular phosphoantigen detection coordinates weak extracellular germline TCR/BTN2A1 and clonotypically influenced TCR/BTN3A-mediated interactions\",\n      \"method\": \"NMR, molecular modeling, mutagenesis, TCR binding assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure with mutagenesis and functional validation in a single rigorous study\",\n      \"pmids\": [\"36995939\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BTN2A1 forms a disulfide-linked homodimer via its B30.2 domain; homodimerization of the BTN2A1 intracellular B30.2 domain is required for phosphoantigen detection; L325G mutation in the BTN2A1 B30.2 domain prevents homodimerization and blocks binding to HMBPP-bound BTN3A1; HMBPP (phosphoantigen) binds BTN3A1 but not BTN2A1; cysteine residues C247 and C265 mediate the disulfide-linked homodimer but are not required for T cell IFN-γ stimulation\",\n      \"method\": \"NMR, size exclusion chromatography, site-directed mutagenesis, isothermal titration calorimetry, [31P]-NMR, ELISA (T cell IFN-γ)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with NMR and mutagenesis, multiple orthogonal methods in single study\",\n      \"pmids\": [\"37171180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Anti-BTN2A1 monoclonal antibody engagement induces SYK recruitment and sequential SYK and ERK phosphorylation in M2-like macrophages, reprogramming them toward an M1-like phenotype; inhibition of SYK or ERK abolishes M2 reprogramming upon BTN2A1 engagement; BTN2A1-reprogrammed macrophages enhance T cell proliferation and IFNγ secretion\",\n      \"method\": \"Anti-BTN2A1 mAb treatment, phosphoprotein analysis (SYK/ERK phosphorylation), kinase inhibitor experiments, in vitro macrophage differentiation assays, ex vivo TAM experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — defined signaling pathway with pharmacological inhibitor validation and multiple functional readouts\",\n      \"pmids\": [\"39325623\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A heterodimeric BTN2A1/BTN3A1 fusion protein provides 'signal 1' to the Vγ9Vδ2 TCR but requires costimulatory signals via CD28 or NKG2D for full T cell activation; a bispecific BTN2A1/BTN3A1-Fc-CD19scFv engager promotes granzyme B-mediated killing of CD19+ lymphoma cells\",\n      \"method\": \"Tumor cell-free assay with BTN2A1/BTN3A1 heterodimeric fusion protein, CD28/NKG2D costimulation experiments, granzyme B cytotoxicity assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reconstituted heterodimer functional assay but single lab, limited mechanistic depth\",\n      \"pmids\": [\"36096643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Anti-BTN2A1 agonist antibody 107G3B5 enhances Vγ9Vδ2 T cell interaction with and killing of tumor cells; Vγ9Vδ2 T cells activated by this antibody trigger caspase 3/7 activation in tumor cells, causing tumor cell death by pyroptosis\",\n      \"method\": \"Cytotoxicity assays, holotomographic microscopy, caspase 3/7 activation assay\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KO/antibody experiments with defined mechanistic phenotype (pyroptosis via caspase 3/7), single lab\",\n      \"pmids\": [\"39302336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BTN2A1 expression on lymphocytes increases via trogocytosis from activated myeloid cells upon CD3/CD28 stimulation; BTN2A1 acquired by BTN2A1-KO B cells through trogocytosis from monocytes confers higher sensitivity to Vγ9Vδ2 T cell lysis; trogocytosis-mediated BTN2A1 acquisition by circulating lymphocytes involves activated monocytes\",\n      \"method\": \"BTN2A1-knockout B cell line, trogocytosis assay, flow cytometry, cytotoxicity assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO cell line with trogocytosis and functional cytotoxicity readout, single lab\",\n      \"pmids\": [\"41066236\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"19F NMR of BTN3A1 point mutants shows that residues W421, T449, and T506 in the BTN3A1 B30.2 domain are conformationally influenced by HMBPP and BTN2A1 association; W421 is at the BTN2A1-binding interface; T506 conformational change upon HMBPP/BTN2A1 binding indicates a larger conformational change in BTN3A1 B30.2 domain propagated beyond the direct phosphoantigen binding site\",\n      \"method\": \"19F solution NMR, BTN3A1 point mutants, binding affinity measurements\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro NMR with mutagenesis and binding affinity measurements, mechanistically detailed\",\n      \"pmids\": [\"40079188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structure of full-length BTN3A1-BTN3A2-BTN2A1 complex shows that phosphoantigen HMBPP bridges the intracellular B30.2 domains of BTN3A1 and BTN2A1; upon TCR engagement, BTN3A2-BTN2A1 ectodomain interaction dissociates, allowing BTN2A1 to bind the lateral surface of the Vγ9 chain while BTN3A2 binds the apical surface of the Vδ2 chain, constituting a 'pliers-like gripping' mechanism for TCR activation; BTN3A2 identified as a bona fide TCR ligand\",\n      \"method\": \"Cryo-EM structural determination of full-length BTN3A1-BTN3A2-BTN2A1 complex and BTN multimer-TCR complex\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structures at multiple states providing mechanistic model, strong structural evidence\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Single oncogenic mutations in healthy organoids are sufficient to upregulate surface BTN2A1 and enable Vγ9Vδ2 TCR binding; full T cell activation additionally requires phosphorylation of juxtamembrane (JTM) amino acids of BTN3A1 leading to activating BTN2A1/BTN3A1 heterodimerization; protein interactome mapping identified PHLDB2, SYNJ2, and CARMIL1 as key regulators of dual surface dynamics of BTN2A1 and BTN3A1 during early transformation\",\n      \"method\": \"Genetically engineered step-wise mutagenesis organoid models, surface BTN2A1 upregulation assays, TCR binding assays, protein interactome mapping\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional organoid models with interactome mapping, preprint not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ICT01 antibody binds a unique region in the extracellular domain of BTN3As, destabilizes the BTN2A1-BTN3As interface, and facilitates Vγ9Vδ2 TCR engagement, thereby activating Vγ9Vδ2 T cells independently of phosphoantigens\",\n      \"method\": \"Structural analysis, biochemical assays, cellular activation assays\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — structural and biochemical characterization but preprint only\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"BTN2A1 is a transmembrane butyrophilin that forms a heteromeric complex with BTN3A1 (and BTN3A2) at the cell surface; intracellularly, phosphoantigen (HMBPP) bridges the B30.2 domains of BTN3A1 and BTN2A1, inducing conformational changes that prime the extracellular BTN2A1 IgV domain to directly bind the Vγ9 chain of the Vγ9Vδ2 TCR as a germline ligand (while BTN3A2 engages the Vδ2 chain), together triggering γδ T cell cytotoxicity; BTN2A1 homodimerization via its B30.2 domain is required for phosphoantigen responsiveness, BTN2A1 also acts as a ligand for DC-SIGN on dendritic cells via high-mannose glycosylation, and in macrophages BTN2A1 engagement signals through SYK and ERK to modulate macrophage polarization.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BTN2A1 is a transmembrane butyrophilin family member that functions as a germline ligand for the Vγ9Vδ2 T cell receptor and a key mediator of phosphoantigen-dependent γδ T cell activation. BTN2A1 forms a heteromeric complex with BTN3A isoforms at the cell surface; intracellularly, the microbial phosphoantigen HMBPP bridges the B30.2 domains of BTN3A1 and BTN2A1, inducing conformational changes that prime the BTN2A1 IgV ectodomain to directly engage the Vγ9 chain of the TCR, while BTN3A2 contacts the Vδ2 chain, together triggering cytotoxicity [PMID:34260935, PMID:36995939, PMID:37171180]. BTN2A1 homodimerization via its B30.2 domain is required for phosphoantigen responsiveness, and TCR and BTN3A1-IgV binding sites on BTN2A1-IgV are mutually exclusive, supporting a composite-ligand model of activation [PMID:37171180, PMID:36995939]. Beyond γδ T cell biology, BTN2A1 serves as a ligand for DC-SIGN on dendritic cells through high-mannose glycosylation [PMID:17785817], and antibody-mediated BTN2A1 engagement on macrophages activates SYK–ERK signaling to reprogram M2-like macrophages toward an M1-like phenotype that enhances T cell responses [PMID:39325623].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Establishing that BTN2A1 is a cell-surface glycoprotein recognized by the innate immune receptor DC-SIGN on dendritic cells, dependent on high-mannose glycosylation, provided the first evidence that BTN2A1 participates in immune cell communication.\",\n      \"evidence\": \"Ig-fusion binding assays, DC-SIGN transfectant binding, antibody blocking, and glycosylation analysis\",\n      \"pmids\": [\"17785817\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Functional consequence of BTN2A1–DC-SIGN interaction on dendritic cell maturation or antigen presentation not determined\",\n        \"Whether DC-SIGN engagement modulates BTN2A1 signaling in the BTN2A1-expressing cell unknown\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of BTN2A1 as an obligate co-receptor with BTN3A1 for Vγ9Vδ2 TCR activation resolved the long-standing question of how phosphoantigen sensing is translated into γδ T cell recognition, showing that BTN2A1 directly contacts the TCR and that its B30.2 domain is required for phosphoantigen responsiveness.\",\n      \"evidence\": \"Co-immunoprecipitation, BTN2A1/BTN3A1 reconstitution in cancer cells, anti-BTN2A1 mAb blocking, and cytotoxicity assays\",\n      \"pmids\": [\"34260935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the BTN2A1–TCR interaction not resolved at this point\",\n        \"Relative contributions of BTN3A isoforms (BTN3A1 vs BTN3A2 vs BTN3A3) to the complex not delineated\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrating that a heterodimeric BTN2A1/BTN3A1 fusion protein delivers 'signal 1' to the Vγ9Vδ2 TCR but requires costimulation for full T cell activation clarified that BTN2A1/BTN3A1 functions analogously to peptide–MHC for γδ T cells.\",\n      \"evidence\": \"Tumor cell-free reconstitution with heterodimeric fusion protein, CD28/NKG2D costimulation, granzyme B cytotoxicity assay\",\n      \"pmids\": [\"36096643\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Costimulatory requirements not validated in vivo\",\n        \"Whether the fusion protein fully recapitulates native complex geometry remains uncertain\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"NMR-based structural mapping revealed that TCR and BTN3A1-IgV bind overlapping sites on BTN2A1-IgV, establishing mutual exclusivity and supporting a composite-ligand model where intracellular phosphoantigen sensing coordinates distinct extracellular TCR contacts.\",\n      \"evidence\": \"NMR, molecular modeling, mutagenesis, TCR binding assays\",\n      \"pmids\": [\"36995939\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Full atomic-resolution structure of the ternary TCR–BTN2A1–BTN3A1 extracellular complex not available from this study\",\n        \"Dynamics of the switch between BTN3A1-bound and TCR-bound states of BTN2A1 not resolved\"\n      ]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Discovering that BTN2A1 forms a disulfide-linked homodimer via its B30.2 domain, and that homodimerization is required for HMBPP-bound BTN3A1 recognition, established a critical intracellular gating mechanism for phosphoantigen sensing.\",\n      \"evidence\": \"NMR, size exclusion chromatography, site-directed mutagenesis (L325G), isothermal titration calorimetry, 31P-NMR\",\n      \"pmids\": [\"37171180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether BTN2A1 homodimerization is regulated by post-translational modifications in vivo not addressed\",\n        \"Stoichiometry of the full signaling complex at the membrane not determined\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Anti-BTN2A1 antibody engagement on M2-like macrophages was shown to recruit SYK and activate SYK–ERK signaling, reprogramming macrophages toward an M1-like state, revealing a previously unrecognized signaling function for BTN2A1 beyond TCR ligand activity.\",\n      \"evidence\": \"Anti-BTN2A1 mAb treatment, SYK/ERK phosphoprotein analysis, kinase inhibitor experiments, in vitro and ex vivo macrophage assays\",\n      \"pmids\": [\"39325623\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Endogenous ligand or physiological trigger for BTN2A1-mediated macrophage signaling not identified\",\n        \"Whether SYK directly binds the BTN2A1 cytoplasmic domain or requires an adaptor unknown\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cryo-EM structures of the full-length BTN3A1–BTN3A2–BTN2A1 complex revealed that HMBPP bridges BTN3A1 and BTN2A1 B30.2 domains intracellularly, and upon TCR engagement the BTN3A2–BTN2A1 ectodomain interaction dissociates so that BTN2A1 grips the Vγ9 chain laterally while BTN3A2 contacts the Vδ2 chain apically, establishing a 'pliers-like' activation mechanism.\",\n      \"evidence\": \"Cryo-EM structural determination of full-length complex and BTN multimer–TCR complex (preprint)\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Preprint not yet peer-reviewed\",\n        \"How membrane lipid environment influences the conformational switch remains unknown\",\n        \"Kinetics of ectodomain dissociation upon phosphoantigen loading not measured\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"19F NMR of BTN3A1 point mutants showed that HMBPP and BTN2A1 association induce conformational changes at residues distant from the phosphoantigen-binding pocket (notably T506), demonstrating allosteric signal propagation through the BTN3A1 B30.2 domain.\",\n      \"evidence\": \"19F solution NMR with BTN3A1 point mutants and binding affinity measurements\",\n      \"pmids\": [\"40079188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How allosteric changes in B30.2 are transmitted across the membrane to the ectodomain not structurally resolved at atomic level\",\n        \"Whether similar allostery occurs in BTN3A2 or BTN3A3 B30.2 domains not tested\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"BTN2A1 can be transferred to lymphocytes via trogocytosis from activated monocytes, and trogocytosis-acquired BTN2A1 is functionally competent to sensitize cells to Vγ9Vδ2 T cell killing, revealing a non-transcriptional mechanism for regulating BTN2A1-dependent γδ T cell surveillance.\",\n      \"evidence\": \"BTN2A1-knockout B cell line, trogocytosis assay, flow cytometry, cytotoxicity assays\",\n      \"pmids\": [\"41066236\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"In vivo relevance of trogocytic BTN2A1 acquisition not demonstrated\",\n        \"Whether trogocytosis transfers the full BTN2A1/BTN3A complex or only BTN2A1 not resolved\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The mechanism by which intracellular phosphoantigen-induced conformational changes in the B30.2 domains are propagated across the membrane to remodel ectodomain architecture, and how BTN2A1's SYK-dependent signaling in macrophages is initiated at the molecular level, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No full transmembrane signaling mechanism linking B30.2 allostery to ectodomain rearrangement\",\n        \"Endogenous trigger for BTN2A1-mediated macrophage SYK signaling unknown\",\n        \"Whether BTN2A1 has a direct cytoplasmic signaling motif or requires adaptor proteins not established\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 2, 5, 9]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 2, 4, 5, 6]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"complexes\": [\n      \"BTN2A1–BTN3A1–BTN3A2 heteromeric complex\",\n      \"BTN2A1 homodimer\"\n    ],\n    \"partners\": [\n      \"BTN3A1\",\n      \"BTN3A2\",\n      \"BTN3A3\",\n      \"DC-SIGN\",\n      \"SYK\",\n      \"PHLDB2\",\n      \"SYNJ2\",\n      \"CARMIL1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}